High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease

Brain

Volumn 137, Issue 3, 2014, Pages 873-886

  Dohler, Frank ^a   Sepulveda Falla, Diego ^a   Krasemann, Susanne ^a   Altmeppen, Hermann ^a   Schlüter, Hartmut ^a   Hildebrand, Diana ^a   Zerr, Inga ^b   Matschke, Jakob ^a   Glatzel, Markus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Alzheimer's disease; amyloid neurodegeneration; amyloid oligomers; prion protein

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; OLIGOMER; PRION PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BINDING ASSAY; BRAIN; BRAIN HOMOGENATE; BRAIN TISSUE; CLINICAL ARTICLE; CLONING; CODON; CONTROLLED STUDY; FEMALE; GEL PERMEATION CHROMATOGRAPHY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; MALE; MIDDLE AGED; MOLECULAR WEIGHT; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; VERY ELDERLY;

ALZHEIMER'S DISEASE; AMYLOID-Β NEURODEGENERATION; AMYLOID-Β OLIGOMERS; PRION PROTEIN; PRPC;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CHROMATOGRAPHY, GEL; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PREFRONTAL CORTEX; PRIONS; PROTEIN BINDING; PRPC PROTEINS;

EID: 84894555460     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awt375     Document Type: Article

References (40)

1. Altmeppen HC, Puig B, Dohler F, Thurm DK, Falker C, Krasemann S, et al. Proteolytic processing of the prion protein in health and disease. Am J Neurodegener Dis 2012; 1: 15-31.
2. Altmeppen HC, Prox J, Puig B, Dohler F, Falker C, Krasemann S, et al. Roles of endoproteolytic alpha-cleavage and shedding of the prion protein in neurodegeneration. FEBS J 2013; 280: 4338-47.
3. Barry AE, Klyubin I, Mc Donald JM, Mably AJ, Farrell MA, Scott M, et al. Alzheimer's disease brain-derived amyloid-beta-mediated inhibition of LTP in vivo is prevented by immunotargeting cellular prion protein. J Neurosci 2011; 31: 7259-63.
4. Beland M, Roucou X. The prion protein unstructured N-terminal region is a broad-spectrum molecular sensor with diverse and contrasting potential functions. J Neurochem 2012; 120: 853-68.
5. Benilova I, De Strooper B. Prion protein in Alzheimer's pathogenesis: a hot and controversial issue. EMBO Mol Med 2010; 2: 289-90.
6. Bergmans BA, De Strooper B. gamma-secretases: from cell biology to therapeutic strategies. Lancet Neurol 2010; 9: 215-26.
7. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
8. Biasini E, Turnbaugh JA, Unterberger U, Harris DA. Prion protein at the crossroads of physiology and disease. Trends Neurosci 2012; 35: 92-103.
9. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
10. Chen S, Yadav SP, Surewicz WK. Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues. J Biol Chem 2010; 285: 26377-83.
11. Colby DW, Prusiner SB. Prions. Cold Spring Harb Perspect Biol 2011; 3: a006833.
12. De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007; 282: 11590-601.
13. Debatin L, Streffer J, Geissen M, Matschke J, Aguzzi A, Glatzel M. Association between deposition of beta-amyloid and pathological prion protein in sporadic Creutzfeldt-Jakob disease. Neurodegener Dis 2008; 5: 347-54.
14. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, et al. Amyloid-beta oligomerization in Alzheimer dementia versus highpathology controls. Ann Neurol 2013; 73: 104-19.
15. Fillenbaum GG, van Belle G, Morris JC, Mohs RC, Mirra SS, Davis PC, et al. Consortium to Establish a Registry for Alzheimer's Disease (CERAD): the first twenty years. Alzheimers Dement 2008; 4: 96-109.
16. Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, et al. An N-terminal fragment of the prion protein binds to amyloid-beta oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 2013; 288: 7857-66.
17. Fonte V, Kapulkin WJ, Taft A, Fluet A, Friedman D, Link CD. Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc Natl Acad Sci USA 2002; 99: 9439-44.
18. Freir DB, Nicoll AJ, Klyubin I, Panico S, Mc Donald JM, Risse E, et al. Interaction between prion protein and toxic amyloid beta assemblies can be therapeutically targeted at multiple sites. Nat Commun 2011; 2: 336.
19. Geissen M, Krasemann S, Matschke J, Glatzel M. Understanding the natural variability of prion diseases. Vaccine 2007; 25: 5631-6.
20. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30: 6367-74.
21. Glatzel M, Ott PM, Linder T, Gebbers JO, Gmur A, Wust W, et al. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol 2003; 2: 757-63.
22. Guillot-Sestier MV, Sunyach C, Druon C, Scarzello S, Checler F. The alpha-secretase-derived N-terminal product of cellular prion, N1, displays neuroprotective function in vitro and in vivo. J Biol Chem 2009; 284: 35973-86.
23. Guillot-Sestier MV, Sunyach C, Ferreira ST, Marzolo MP, Bauer C, Thevenet A, et al. alpha-Secretase-derived fragment of cellular prion, N1, protects against monomeric and oligomeric amyloid beta (Abeta)-associated cell death. J Biol Chem 2012; 287: 5021-32.
24. Lal A, Haynes SR, Gorospe M. Clean Western blot signals from immunoprecipitated samples. Mol Cell Probes 2005; 19: 385-8.
25. Larson M, Sherman MA, Amar F, Nuvolone M, Schneider JA, Bennett DA, et al. The complex PrP(c)-Fyn couples human oligomeric Abeta with pathological tau changes in Alzheimer's disease. J Neurosci 2012; 32: 16857-71a.
26. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloidbeta oligomers. Nature 2009; 457: 1128-32.
27. Lesne SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, et al. Brain amyloid-beta oligomers in ageing and Alzheimer's disease. Brain 2013; 136: 1383-98.
28. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, et al. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J Biol Chem 2009; 284: 32895-905.
29. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
30. Resenberger UK, Harmeier A, Woerner AC, Goodman JL, Muller V, Krishnan R, et al. The cellular prion protein mediates neurotoxic signalling of beta-sheet-rich conformers independent of prion replication. EMBO J 2011; 30: 2057-70.
31. Rushworth JV, Griffiths HH, Watt NT, Hooper NM. Prion proteinmediated toxicity of amyloid-beta oligomers requires lipid rafts and the transmembrane LRP1. J Biol Chem 2013; 288: 8935-51.
32. Sepulveda-Falla D, Matschke J, Bernreuther C, Hagel C, Puig B, Villegas A, et al. Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol 2011; 21: 452-63.
33. Ray I, Chauhan A, Wisniewski HM, Wegiel J, Kim KS, Chauhan VP. Binding of amyloid beta-protein to intracellular brain proteins in rat and human. Neurochem Res 1998; 23: 1277-82.
34. Um JW, Nygaard HB, Heiss JK, Kostylev MA, Stagi M, Vortmeyer A, et al. Alzheimer amyloid-beta oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci 2012; 15: 1227-35.
35. Um JW, Strittmatter SM. Amyloid-beta induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease. Prion 2013; 7: 37-41.
36. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002; 416: 535-9.
37. Weidemann A, Konig G, Bunke D, Fischer P, Salbaum JM, Masters CL, et al. Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein. Cell 1989; 57: 115-26.
38. Westaway D, Jhamandas JH. The P's and Q's of cellular PrP-Abeta interactions. Prion 2012; 6: 359-63.
39. Younan ND, Sarell CJ, Davies P, Brown DR, Viles JH. The cellular prion protein traps Alzheimer's Abeta in an oligomeric form and disassembles amyloid fibers. FASEB J 2013; 27: 1847-58.
40. Zou WQ, Xiao X, Yuan J, Puoti G, Fujioka H, Wang X, et al. Amyloidbeta42 interacts mainly with insoluble prion protein in the Alzheimer brain. J Biol Chem 2011; 286: 15095-105.